Abstract:BACKGROUND AND AIMS:Defective autophagy has been proposed as an important event in a growing number of autoimmune and inflammatory diseases such as rheumatoid arthritis and lupus. However, the precise role of mechanistic target of rapamycin (mTOR)-dependent autophagy and its underlying regulatory mechanisms in the intestinal epithelium in response to inflammation and oxidative stress remain poorly understood.METHODS:The levels of p-mTOR, LC3B, p62 and autophagy in mice and LPS-treated cells were examined by immunoblotting, immunohistochemistry, confocal microscopy and transmission electron microscopy (TEM). We evaluated the expression of IL-1β, IL-8, TNF-α, MDA, SOD and T-AOC by quantitative real time-polymerase chain reaction (qRT-PCR) and commercially available kits after silencing of mTOR and ATG5. In vivo modulation of mTOR and autophagy was achieved by using AZD8055, rapamycin and 3-methyladenine. Finally, to verify the involvement of TLR4 signalling and the NF-κB pathway in cells and active ulcerative colitis (UC) patients, immunofluorescence, qRT-PCR, immunoblotting and TEM were performed to determine TLR4 signalling relevance to autophagy and inflammation.RESULTS:The mTOR-dependent autophagic flux impairment in a murine model of colitis, human intestinal epithelial cells and active UC patients is probably regulated by TLR4-MyD88-MAPK signalling and the NF-κB pathway. Silencing mTOR remarkably attenuated, whereas inhibiting ATG5 aggravated, LPS-induced inflammation and oxidative injury. Pharmacological administration of mTOR inhibitors and autophagy stimulators markedly ameliorated experimental colitis and oxidative stress in vivo.CONCLUSIONS:Our findings not only shed light on the regulatory mechanism of mTOR-dependent autophagy, but also provided potential therapeutic targets for intestinal inflammatory diseases such as refractory inflammatory bowel disease.

Mtorc1 Signaling and IL‐17 Expression: Defining Pathways and Possible Therapeutic Targets

TAOK1 Negatively Regulates IL-17-mediated Signaling and Inflammation

Mtor Signaling in T Cell Immunity and Autoimmunity

Inactivation of the Enzyme GSK3α by the Kinase IKKi Promotes AKT-mTOR Signaling Pathway that Mediates Interleukin-1-Induced Th17 Cell Maintenance

An Autonomous Activation of Interleukin-17 Receptor Signaling Sustains Inflammation and Promotes Disease Progression.

Rkip Mediates Autoimmune Inflammation By Positively Regulating Il-17r Signaling

The Activation and Regulation of IL-17 Receptor Mediated Signaling

MTOR Suppresses Autophagy-Mediated Production of IL25 in Allergic Airway Inflammation

Boosting Mtor-Dependent Autophagy Via Upstream TLR4-MyD88-MAPK Signalling and Downstream NF-κB Pathway Quenches Intestinal Inflammation and Oxidative Stress Injury

IL-17/IL-17 Receptor System in Autoimmune Disease: Mechanisms and Therapeutic Potential

TRAF Regulation of IL-17 Cytokine Signaling

Mtor Complexes Differentially Orchestrates Eosinophil Development in Allergy.

mTOR promotes an inflammatory response through the HIF1 signaling pathway in ulcerative colitis

Mtor Signaling: A Pivotal Player in Treg Cell Dysfunction in Systemic Lupus Erythematosus.

mTORC2 contributes to systemic autoimmunity

MYC-mediated Silencing of Mir-181A-5p Promotes Pathogenic Th17 Responses by Modulating AKT3-FOXO3 Signaling

IL-17A activates JAK/STAT signaling to affect drug metabolizing enzymes and transporters in HepaRG cells

Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation

MiR-let-7d-3p Regulates IL-17 Expression Through Targeting AKT1/mTOR Signaling in CD4+ T Cells

Therapeutic potential of interleukin-17 in inflammation and autoimmune diseases.

Modulation of TSC-mTOR Signaling on Immune Cells in Immunity and Autoimmunity.